Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BHC

BHC - Bausch Health Cos Inc Stock Price, Fair Value and News

$4.96-0.09 (-1.78%)
Market Closed

50/100

BHC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

BHC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BHC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BHC Price Action

Last 7 days

-7.8%

Last 30 days

-18.4%

Last 90 days

-28.3%

Trailing 12 Months

-28.0%

BHC RSI Chart

BHC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BHC Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

11.71

Price/Sales (Trailing)

0.18

EV/EBITDA

6.6

Price/Free Cashflow

1.83

BHC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BHC Fundamentals

BHC Revenue

Revenue (TTM)

10.3B

Rev. Growth (Yr)

9.26%

Rev. Growth (Qtr)

4.29%

BHC Earnings

Earnings (TTM)

157.0M

Earnings Growth (Yr)

-220.43%

Earnings Growth (Qtr)

-162.57%

BHC Profitability

EBT Margin

3.57%

Return on Equity

41.64%

Return on Assets

0.6%

Free Cashflow Yield

54.57%

BHC Investor Care

Dividend Yield

21.59%

Dividend/Share (TTM)

1.28

Shares Dilution (1Y)

0.71%

Diluted EPS (TTM)

0.42

BHC Alerts

  • 2 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.7B9.9B10.0B10.3B
20249.0B9.2B9.5B9.6B
20238.2B8.3B8.5B8.8B
20228.3B8.2B8.1B8.1B
20218.0B8.5B8.5B8.4B
20208.6B8.1B8.0B8.0B
20198.4B8.4B8.5B8.6B
20188.6B8.5B8.4B8.4B
20179.4B9.2B9.0B8.7B
201610.7B10.3B10.0B9.7B
20158.5B9.2B9.9B10.4B
20146.6B7.5B8.0B8.2B
20133.7B4.0B4.6B5.8B
20122.7B2.9B3.2B3.5B
20111.5B1.9B2.3B2.4B
Get all data in R, Python etc through our Historical Stock Data APIs

About Bausch Health Cos Inc

BHC
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.
 CEO
 WEBSITEbauschhealth.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES19900

Bausch Health Cos Inc Frequently Asked Questions

BHC is the stock ticker symbol of Bausch Health Cos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Bausch Health Cos Inc is 1.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, BHC's PE ratio (Price to Earnings) is 11.71 and Price to Sales (PS) ratio is 0.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BHC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Bausch Health Cos Inc has provided -0.174 (multiply by 100 for percentage) rate of return.